The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-related morbidity, mortality, and costs: A systematic review

Clinical Infectious Diseases

Volumn 46, Issue 11, 2008, Pages 1717-1725

  McGinigle, Katharine L ^a,b,d   Gourlay, Margaret L ^a,b   Buchanan, Ian B ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW;

ADULT; HUMANS; INTENSIVE CARE UNITS; METHICILLIN RESISTANCE; MORBIDITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 43949125890     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587901     Document Type: Review

References (51)

1. Harrison S. Battling to beat the bugs. Nurs Stand 2004; 18:12-3.
2. Division of Healthcare Quality Promotion. Healthcare-associated infections. 2006. Available at: http://www.cdc.gov/ncidod/dhqp/healthDis. html. Accessed 20 April 2007.
3. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24:362-86.
4. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481-98.
5. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in healthcare settings, 2006. 2006. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf. Accessed 14 April 2007.
6. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9.
7. Whitby M, McLaws ML, Berry G. Risk of death from methicillinresistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001; 175:264-7.
8. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592-8.
9. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368:874-85.
10. Talbot TR. Two studies feed the debate on active surveillance for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci carriage: to screen or not to screen? J Infect Dis 2007; 195:314-7.
11. Marshall C, Wesselingh S, McDonald M, Spelman D. Control of endemic MRSA - what is the evidence? A personal view. J Hosp Infect 2004; 56:253-68.
12. Bradley SF. Eradication or decolonization of methicillin-resistant Staphylococcus aureus carriage: what are we doing and why are we doing it? Clin Infect Dis 2007; 44:186-9.
13. Warren DK, Guth RM, Coopersmith CM, Merz LR, Zack JE, Fraser VJ. Epidemiology of methicillin-resistant Staphylococcus aureus colonization in a surgical intensive care unit. Infect Control Hosp Epidemiol 2006; 27:1032-40.
14. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001; 29(4 Suppl):N64-8.
15. Institute of Healthcare Improvement: 5 Million Lives Campaign. 2006. Available at: http://www.ihi.org/IHI/Programs/Campaign/Campaign. htm?TabIdp1. Accessed 14 April 2007.
16. Khan KS, Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CDR's guidance for those carrying out or commissioning reviews. 2nd ed. London: Health Protection Agency, Centre for Reviews and Dissemination, 2001.
17. Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001; 20(3 Suppl):36-43.
18. Huang SS, Rifas-Shiman SL, Warren DK, et al. Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis 2007; 195:330-8.
19. Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2006; 43:971-8.
20. Gould IM. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents 2006;28:379-84.
21. Wernitz MH, Swidsinski S, Weist K, et al. Effectiveness of a hospitalwide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers at hospital admission to prevent hospital-acquired MRSA infections. Clin Microbiol Infect 2005; 11:457-65.
22. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999; 282:1745-51.
23. Sandri AM, Dalarosa MG, Ruschel de Alcantara L, da Silva Elias L, Zavascki AP. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol 2006; 27:185-7.
24. Shitrit P, Gottesman BS, Katzir M, Kilman A, Ben-Nissan Y, Chowers M. Active surveillance for methicillin-resistant Staphylococcus aureus (MRSA) decreases the incidence of MRSA bacteremia. Infect Control Hosp Epidemiol 2006; 27:1004-8.
25. West TE, Guerry C, Hiott M, Morrow N, Ward K, Salgado CD. Effect of targeted surveillance for control of methicillin-resistant Staphylococcus aureus in a community hospital system. Infect Control Hosp Epidemiol 2006; 27:233-8.
26. Eveillard M, Lancien E, Barnaud G, et al. Impact of screening for MRSA carriers at hospital admission on risk-adjusted indicators according to the imported MRSA colonization pressure. J Hosp Infect 2005; 59:254-8.
27. Lucet JC, Paoletti X, Lolom I, et al. Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Med 2005; 31:1051-7.
28. Nijssen S, Bonten MJ, Weinstein RA. Are active microbiological surveillance and subsequent isolation needed to prevent the spread of methicillin-resistant Staphylococcus aureus? Clin Infect Dis 2005; 40:405-9.
29. Pan A, Carnevale G, Catenazzi P, et al. Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA. Infect Control Hosp Epidemiol 2005; 26:127-33.
30. Troche G, Joly LM, Guibert M, Zazzo JF. Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol 2005; 26:161-5.
31. Thompson DS. Methicillin-resistant Staphylococcus aureus in a general intensive care unit. J R Soc Med 2004; 97:521-6.
32. Tomic V, Svetina Sorli P, Trinkaus D, Sorli J, Widmer AF, Trampuz A. Comprehensive strategy to prevent nosocomial spread of methicillin-resistant Staphylococcus aureus in a highly endemic setting. Arch Intern Med 2004; 164:2038-43.
33. Souweine BTO, Aublet-Cuvelier B, Bret L, Sirot J, Laveran H, Deteix P. Role of infection control measures in limiting morbidity associated with multi-resistant organisms in critically ill patients. J Hosp Infect 2000; 45:107-16.
34. Lucet JC, Chevret S, Durand-Zaleski I, Chastang C, Regnier B. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med 2003; 163:181-8.
35. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 2005; 11:466-71.
36. Gavalda L, Masuet C, Beltran J, et al. Comparative cost of selective screening to prevent transmission of methicillin-resistant Staphylococcus aureus (MRSA), compared with the attributable costs of MRSA infection. Infect Control Hosp Epidemiol 2006; 27:1264-6.
37. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001; 22:99-104.
38. Farr BM. What to think if the results of the National Institutes of Health randomized trial of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus control measures are negative (and other advice to young epidemiologists): a review and an au revoir. Infect Control Hosp Epidemiol 2006; 27:1096-106.
39. Weber SG, Huang SS, Oriola S, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Am J Infect Control 2007; 35:73-85.
40. Maryland General Assembly. Hospitals and nursing facilities - health care associated infections prevention and control program. 2006. Available at: http://mlis.state.md.us/2006rs/billfile/hb0966.htm. Accessed 9 October 2007.
41. Illinois General Assembly Bill Status of SB2771, 94th General Assembly. 2006. Available at: http://www.ilga.gov/legislation/BillStatus.asp? GAp94&DocTypeIDpSB&DocNump2771&GAIDp8&SessionIDp50& LegIDp23855. Accessed 9 October 2007.
42. Pennsylvania General Assembly Senate Bill 968PN1298. 2007. Available at: http://www.legis.state.pa.us/CFDOCS/Legis/PN/Public/btCheck.cfm? txtType=HTM&sessYr=2007&sessInd=0&billBody=S&billTyp= B&billnbr=0968&pn=1298. Accessed 9 October 2007.
43. Verhoef J, Beaujean D, Blok H, et al. A Dutch approach to methicillinresistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1999; 18:461-6.
44. Kotilainen P, Routamaa M, Peltonen R, et al. Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions, Finland. Emerg Infect Dis 2003; 9:169-75.
45. Kunori T, Cookson B, Roberts JA, Stone S, Kibbler C. Cost-effectiveness of different MRSA screening methods. J Hosp Infect 2002; 51:189-200.
46. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003:CD003340.
47. Kirkland KB, Weinstein JM. Adverse effects of contact isolation. Lancet 1999; 354:1177-8.
48. Evans HL, Shaffer MM, Hughes MG, et al. Contact isolation in surgical patients: a barrier to care? Surgery 2003; 134:180-8.
49. Boyce JM, Pittet D; Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR Recomm Rep 2002; 51(RR-16):1-45, quiz CE1-4.
50. Weber DJ, Sickbert-Bennett EE, Brown VM, et al. Compliance with isolation precautions at a university hospital. Infect Control Hosp Epidemiol 2007; 28:358-61.
51. Afif W, Huor P, Brassard P, Loo VG. Compliance with methicillin-resistant Staphylococcus aureus precautions in a teaching hospital. Am J Infect Control 2002; 30:430-3.